Cluster B: 7 High Throughput Screening

UI高通量筛查核心（HTS）是一个新的霍尔顿综合癌症中心（HCCC） 共享研究资源，提供高通量平台，集成机器人技术，检测系统， 化学/生物制品库、数据管理和专业知识。HTS为HCCC成员提供可扩展的 治疗药物的早期临床前开发，包括小分子治疗药物、抗体、siRNAs， 反义寡核苷酸和其它生物制剂，包括源自患者的细胞治疗剂。它还支持高 用于探索癌症生物学的研究的通量筛选。 自动化、小型化和并行的高通量方法促进了药物的命中和铅的产生。 通过筛选系统的、无偏见的大型化学/生物制品库来发现和开发。 这些策略还促进了用于化学药物作用机制（MOA）研究的分子探针发现。 生物学通过筛选集中的智力设计的化合物集合。此外，这些高... 通过量方法有助于对细胞，特别是来自患者的细胞进行分析。 HTS于2012年由大学赞助商建立，包括HCCC和NIH S10共享 工具补助金。HTS配备了在96-、384-和1536-中进行高通量筛选的设备。 孔格式，用酶标仪检测（Perkin-Elmer EnVision），使用吸光度、荧光和 发光，包括先进的FRET和BRET技术。HTS还可以执行高内容筛选 (HCS Perkin-Elmer Operetta共聚焦成像系统）来检测和定量表型变化，即细胞凋亡。 细胞分化、细胞迁移、神经突生长和靶向运输;或靶向细胞的荧光强度。 蛋白质表达、转录因子或信号通路分析。HTS中可用的系统包括 与用于平板处理和分析执行的机器人集成，适用于小规模或大规模化合物 自动化程度“随时可达”的图书馆屏幕。HTS目前拥有五个“小分子”库 含有大约14万种化合物。此外，HTS正在确定需要和 获得生物制品文库的可行性，即全基因组siRNA、抗体和不同的细胞系。 总体而言，HTS是一个共享的研究资源，专注于药物发现的可扩展筛选方法， 开发和分子探针发现，用于癌症研究人员的作用机制研究， 校园内外

The UI High Throughput Screening Core (HTS) is a new Holden Comprehensive Cancer Center (HCCC) shared research resource that provides a high-throughput platform integrating robotics, detection systems, chemical /biologics libraries, data management, and expertise. HTS provides HCCC members with scalable early, pre-clinical development of therapeutics, including small molecule therapeutics, antibodies, siRNAs, antisense oligonucleotides and other biologics including patient-derived cell therapeutics. It also supports high throughput screening for studies exploring the biology of cancer. The automatic, miniaturized and parallel high-throughput approaches foster hit and lead generation for drug discovery and development through screening of systematic, unbiased large chemical/biologics libraries. These strategies also facilitate molecular probe discovery for mechanism-of-action (MOA) studies of chemical biology through screening of focused intellectually designed compound collections. In addition, these high- throughput approaches aid the interrogation of cells, especially those derived from patients. The HTS was established in 2012 by university sponsors including the HCCC and an NIH S10 Shared Instrumentation grant funding. HTS is equipped to perform high-throughput screening in 96-, 384- and 1536- well formats, with plate reader detection (Perkin-Elmer EnVision) using absorbance, fluorescence and luminescence, including advanced FRET and BRET techniques. HTS can also perform high content screening (HCS, Perkin-Elmer Operetta Confocal Imaging System) to detect and quantify phenotypic changes, i.e. cell differentiation, cell migration, neurite outgrowth, and target trafficking; or by fluorescence intensities for target protein expression, transcription factor or signaling pathway analysis. Systems available in the HTS are integrated with robotics for plate handling and assay execution, suitable for small- or large-scale compound library screens with “walk-away” levels of automation. HTS currently holds five “small molecule” libraries containing approximately 140,000 compounds. In addition, HTS is in the process of determining the need and feasibility of obtaining a biologics library, i.e. genome-wide siRNA, antibodies, and diverse cell lines. Overall, HTS is a shared research resource focused on scalable screening approaches for drug discovery and development, and molecular probe discovery for mechanism-of-action studies for cancer investigators across campus and beyond.